NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis → 1k a day while computer does all work? (From Digital Mavericks Media) (Ad) Free ANNX Stock Alerts $4.73 +0.03 (+0.64%) (As of 05/30/2024 ET) Add Compare Share Share Today's Range$4.66▼$4.9150-Day Range$4.33▼$7.8152-Week Range$1.57▼$8.40Volume680,721 shsAverage Volume1.55 million shsMarket Capitalization$437.10 millionP/E RatioN/ADividend YieldN/APrice Target$15.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Annexon alerts: Email Address Annexon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside224.2% Upside$15.33 Price TargetShort InterestBearish8.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 4 Articles This WeekInsider TradingAcquiring Shares$19,424 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.99) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector514th out of 930 stocksPharmaceutical Preparations Industry238th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Annexon's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.19% of the outstanding shares of Annexon have been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Annexon has recently increased by 25.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANNX. Previous Next 3.3 News and Social Media Coverage News SentimentAnnexon has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Annexon this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows8 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,424.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.67% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Annexon are expected to decrease in the coming year, from ($0.99) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProDo This Before July 30 2024 To Claim Trump’s Gift In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Annexon Stock (NASDAQ:ANNX)Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More ANNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANNX Stock News HeadlinesMay 30 at 8:06 AM | americanbankingnews.comShort Interest in Annexon, Inc. (NASDAQ:ANNX) Rises By 25.3%May 16, 2024 | globenewswire.comAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)May 14, 2024 | markets.businessinsider.comBuy Rating on Annexon Biosciences Backed by Efficacious ANX007 Data and Meticulous Phase 3 Trial DesignMay 14, 2024 | finance.yahoo.comWe Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business GrowthMay 13, 2024 | globenewswire.comAnnexon Reports First Quarter 2024 Financial Results and Key Anticipated MilestonesMay 9, 2024 | globenewswire.comAnnexon Biosciences to Present at the Bank of America Health Care ConferenceMay 7, 2024 | globenewswire.comAnnexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual MeetingMay 1, 2024 | globenewswire.comAnnexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual MeetingApril 20, 2024 | morningstar.comAnnexon Inc Ordinary SharesApril 17, 2024 | finance.yahoo.comAre Medical Stocks Lagging Annexon (ANNX) This Year?April 17, 2024 | finance.yahoo.comAre Medical Stocks Lagging Annexon (ANNX) This Year?April 16, 2024 | globenewswire.comAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | markets.businessinsider.comBuy Rating on Annexon Biosciences: Promising Pipeline and Strategic Growth PotentialApril 3, 2024 | globenewswire.comAnnexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)March 28, 2024 | markets.businessinsider.comAnticipating Growth: Positive Outlook for Annexon Biosciences Amid Upcoming Clinical Trials and New Data ReadoutsMarch 27, 2024 | finanznachrichten.deAnnexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated MilestonesMarch 27, 2024 | markets.businessinsider.comAnnexon Biosciences (ANNX) Receives a Buy from TD CowenMarch 26, 2024 | globenewswire.comAnnexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated MilestonesMarch 18, 2024 | globenewswire.comAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)March 16, 2024 | ca.finance.yahoo.comANNX Jul 2024 7.500 putMarch 16, 2024 | ca.finance.yahoo.comANNX Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comANNX Apr 2024 7.500 putMarch 16, 2024 | finance.yahoo.comNational group to cut realtor commissions, make home-buying more affordableMarch 15, 2024 | finance.yahoo.comCannabis Grower Ascend Seeks Private Loan to Refinance DebtSee More Headlines Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today5/30/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANNX CUSIPN/A CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$15.33 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+224.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.52% Return on Assets-46.50% Debt Debt-to-Equity RatioN/A Current Ratio20.61 Quick Ratio20.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book1.67Miscellaneous Outstanding Shares92,410,000Free Float80,704,000Market Cap$437.10 million OptionableOptionable Beta1.29 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Douglas Love Esq. (Age 56)J.D., CEO, President & Director Comp: $980.12kDr. Dean R. Artis Ph.D. (Age 63)Chief Scientific Officer & Executive VP Comp: $797.38kDr. Ted Yednock Ph.D. (Age 66)Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board Comp: $697.76kMs. Jennifer Lew (Age 51)Executive VP, CFO & Corporate Secretary Comp: $624.2kMr. Michael Overdorf M.B.A. (Age 53)Executive VP & Chief Business Officer Comp: $580.47kHenk-Andre Kroon M.D.Senior Vice President of Translational MedicineDr. Jamie Dananberg M.D. (Age 66)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPHEnanta PharmaceuticalsNASDAQ:ENTAPliant TherapeuticsNASDAQ:PLRXZai LabNASDAQ:ZLABGalapagosNASDAQ:GLPGView All CompetitorsInsiders & InstitutionsVirtu Financial LLCSold 2,884 shares on 5/20/2024Ownership: 0.049%Ikarian Capital LLCSold 1,245,000 shares on 5/17/2024Ownership: 1.542%Comerica BankBought 10,000 shares on 5/17/2024Ownership: 0.011%Kennedy Capital Management LLCSold 301,032 shares on 5/16/2024Ownership: 0.850%Bayesian Capital Management LPBought 16,599 shares on 5/16/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions ANNX Stock Analysis - Frequently Asked Questions Should I buy or sell Annexon stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANNX shares. View ANNX analyst ratings or view top-rated stocks. What is Annexon's stock price target for 2024? 6 brokerages have issued 1 year price targets for Annexon's shares. Their ANNX share price targets range from $10.00 to $30.00. On average, they predict the company's stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 224.2% from the stock's current price. View analysts price targets for ANNX or view top-rated stocks among Wall Street analysts. How have ANNX shares performed in 2024? Annexon's stock was trading at $4.54 at the beginning of 2024. Since then, ANNX stock has increased by 4.2% and is now trading at $4.73. View the best growth stocks for 2024 here. Are investors shorting Annexon? Annexon saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 7,570,000 shares, an increase of 25.3% from the April 30th total of 6,040,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 4.0 days. View Annexon's Short Interest. When is Annexon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our ANNX earnings forecast. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.11. What ETF holds Annexon's stock? iShares Neuroscience and Healthcare ETF holds 4,459 shares of ANNX stock, representing 0.60% of its portfolio. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE). When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. Who are Annexon's major shareholders? Annexon's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (9.55%), Vanguard Group Inc. (4.11%), Bellevue Group AG (2.39%), Ikarian Capital LLC (1.54%), Price T Rowe Associates Inc. MD (1.45%) and Acadian Asset Management LLC (1.05%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Jennifer Lew, Michael Overdorf, Muneer A Satter, Ted Yednock and William H Carson. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANNX) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBiden Nomination CANCELED?The Freeport SocietyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeGet out of dollars—get into America’s new money insteadStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
